Compare MTG & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MTG | BLCO |
|---|---|---|
| Founded | 1957 | 1853 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Ophthalmic Goods |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 6.0B |
| IPO Year | 2008 | 2022 |
| Metric | MTG | BLCO |
|---|---|---|
| Price | $26.88 | $18.04 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 12 |
| Target Price | ★ $27.50 | $18.55 |
| AVG Volume (30 Days) | ★ 2.1M | 452.4K |
| Earning Date | 05-04-2026 | 05-21-2026 |
| Dividend Yield | ★ 2.25% | N/A |
| EPS Growth | ★ 8.65 | N/A |
| EPS | ★ 3.14 | N/A |
| Revenue | $1,213,636,000.00 | ★ $5,101,000,000.00 |
| Revenue This Year | $3.24 | $7.45 |
| Revenue Next Year | $1.52 | $5.49 |
| P/E Ratio | $8.53 | ★ N/A |
| Revenue Growth | 0.49 | ★ 6.47 |
| 52 Week Low | $21.94 | $10.45 |
| 52 Week High | $29.97 | $18.92 |
| Indicator | MTG | BLCO |
|---|---|---|
| Relative Strength Index (RSI) | 49.34 | 56.00 |
| Support Level | $25.55 | $16.35 |
| Resistance Level | $26.92 | N/A |
| Average True Range (ATR) | 0.59 | 0.64 |
| MACD | 0.09 | 0.07 |
| Stochastic Oscillator | 56.02 | 63.79 |
MGIC Investment Corp provides private mortgage insurance, other mortgage credit risk management solutions, and ancillary services. The insurance premiums that these customers pay for the protection accounts for close to majority of the company's total revenue. Investment income accounts for the remaining revenue. The company sells its insurance products in all states of the United States and in Puerto Rico. Its greatest exposure is in California, Florida, Texas, Pennsylvania, Ohio, Illinois, Virginia, North Carolina, Georgia and New York.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.